Medicis shares surge after settlement
The drugmaker says it cuts a deal to end a patent dispute over a generic version of the acne drug Solodyn.
 |
| The companies announced a settlement of the patent dispute over a generic version of the acne drug Solodyn. |
NEW YORK (CNNMoney.com) -- Shares of Medicis Pharmaceutical Corp. rose more than 25% in midday trading Tuesday, following the settlement of a patent dispute with a competitor.
Late Monday, Medicis (MRX) announced it cut a deal with Impax Laboratories Inc., ending a patent dispute over a generic version of the acne drug Solodyn.
At 12:30 p.m. ET, Medicis shares were up $2.81 to $13.93.
According to the announcement, Impax retains the right to market a generic version no later than November 2011. After launching its drug, the conpanies said Impax will pay Medicis a royalty based on sales.
The companies will also collaborate on research and development of five "strategic dermatology product opportunities," including a more advanced version of Solodyn, according to a statement issued by the companies.
The companies said Impax has agreed that Medicis' patents relating to Solodyn are valid and enforceable. 
-
Steve Jobs revived Apple, defying the worst economic conditions since the Great Depression. More -
Consumers looking to buy electronics for holiday gifts won't have to break the bank this season. More -
Search firm says it will pay the bill for wireless Internet during the holidays. More -
Twitter and LinkedIn hook up, signing agreement to let users share information across both platforms. More -
The search firm is investing heavily in Google Earth, but will its gamble be profitable? Play -
Anne Giapapas has a job in one of the 15 most overworked and underpaid professions. More -
These 5 businesses are offering their services -- from shoes to hair cuts -- to the unemployed. More
